PHASE 3

A Trial of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (mCRC)

Key Inclusion Criteria

• Age ≥18 years
• ECOG PS 0 or 1
• Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic
• Failed treatment with a minimum of 6 weeks of first-line combination therapy for metastatic disease that included bevacizumab (if applicable), oxaliplatin, and a fluoropyrimidine in the same cycle. Treatment failure is defined as radiologic progression during or <6 months after the last dose of first-line treatment
• FOLFIRI therapy is appropriate for the patient and is recommended by the Investigator

Study Locations

Please check www.clinicaltrials.gov for updates about this study (NCT02753127) and site locations.

About Napabucasin

Napabucasin is an investigational, orally administered agent hypothesized to inhibit multiple oncogenic pathways, and has not yet been approved by the FDA or any other health authorities.

See ClinicalTrials.gov for comprehensive eligibility criteria.

FOLFIRI=5-fluorouracil 400 mg/m² bolus followed by 1200 mg/m²/day continuous infusion, leucovorin 400 mg/m², and irinotecan 180 mg/m²; IV=intravenously; RECIST 1.1=Response Evaluation Criteria in Solid Tumors version 1.1; pSTAT3=phosphorylated signal transducer and activator of transcription 3; ECOG PS=Eastern Cooperative Oncology Group Performance Status.

Boston Biomedical, Inc. is a leading developer of novel cancer therapeutics with the goal of significantly improving patient outcomes.
PHASE 3

A Trial of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (mCRC)